Skip to content

LSD: all studies

Page 35 of 282: studies 341 to 350 of 2,815, newest first. Back to the LSD overview

Research

Serotonin type 5A receptor antagonists inhibit D-lysergic acid diethylamide discriminatory cue in rats

Journal of Psychopharmacology November 1, 2019 Piotr Popik, Martyna Krawczyk, Agata Kuziak et al.

Purpose: Like other psychedelics, D-lysergic acid diethylamide (LSD) affects numerous serotonin receptors, and according to the current dogma, the 5-HT 2A receptors are considered the main target for its hallucinogenic effects. LSD, however, also displays agonistic activity at the 5-HT 5A receptors, which mediate some of LSD-induced behavioural effects. Methods: Using male Sprague Dawley rats,...

Acute effects of lysergic acid diethylamide (LSD) on resting brain function

Swiss Medical Weekly September 30, 2019 Felix Mller, Stefan Borgwardt 10 citations

Lysergic acid diethylamide (LSD) is a potent hallucinogenic substance that was extensively investigated by psychiatrists during the 1950s and 1960s. Researchers were interested in the unique effects induced by this substance, some of which resemble symptoms seen in schizophrenia. Moreover, during that period LSD was studied and used for the treatment of several mental disorders such as...

LSD acutely impairs working memory, executive functions, and cognitive flexibility, but not risk-based decision-making

Psychological Medicine September 10, 2019 Thomas Pokorny, Patricia Duerler, Erich Seifritz et al. 102 citations

Abstract Background Psychiatric and neurodegenerative illnesses are characterized by cognitive impairments, in particular deficits in working memory, decision-making, and executive functions including cognitive flexibility. However, the neuropharmacology of these cognitive functions is poorly understood. The serotonin (5-HT) 2A receptor might be a promising candidate for the modulation of...

DOI: 10.1017/s0033291719002393 (opens in new tab) Cognitive flexibility Working memory Executive functions Cognition +2

MICRODOSING PSYCHEDELICS - LSD, WHERE COULD IT GO?

August 14, 2019 S. Penedos, I. Figueiredo, Maria Margarida Magalhães Lopes et al.

BACKGROUNDMicrodosing of psychedelics such as LSD consists in its regular ingestion of a non-hallucinogenic dose. Advocates deny experiencing the typical alterations in consciousness while reporting various long-lasting psychological benefits.It has been under research for treatment of mental health disorders including end-of-life anxiety, drug abuse, and depression. Increased accessibility in...

The Trials of Psychedelic Therapy: LSD Psychotherapy in America By Matthew Dram Johns Hopkins University Press. 2018. 288 pp. £33.30 (hb). ISBN 9781421426204.

The British Journal of Psychiatry July 10, 2019 B. Sessa 1 citation

An abstract is not available for this content. As you have access to this content, full HTML content is provided on this page. A PDF of this content is also available in through the ‘Save PDF’ action button.

Metabolism of lysergic acid diethylamide (LSD): an update

Drug Metabolism Reviews July 3, 2019 Rui Filipe Libânio Osório Marta 52 citations

Lysergic acid diethylamide (LSD) is the most potent hallucinogen known and its pharmacological effect results from stimulation of central serotonin receptors (5-HT2). Since LSD is seen as physiologically safe compound with low toxicity, its use in therapeutics has been renewed during the last few years. This review aims to discuss LSD metabolism, by presenting all metabolites as well as...

“Go ask Alice, when she’s 10-feet tall”: Psychosocial correlates to lifetime LSD use among a national sample of US adults

Journal of Psychedelic Studies June 26, 2019 R. Andrew Yockey, Keith A. King, Rebecca A. Vidourek 18 citations

Introduction Once thought a rarely used drug, LSD use is steadily increasing among US adults. A greater understanding of social factors and psychological determinants leading to lifetime LSD use can assist health educators and professionals in treating this growing problem. This study analyzed psychosocial factors related to LSD use among a national sample of adults. Methods A secondary data...

DOI: 10.1556/2054.2019.014 (opens in new tab) Full text (opens in new tab) Psychosocial Sample material Logistic regression Clinical psychology +3

Psychedelic crossings: American mental health and LSD in the 1970s.

Medical Humanities June 23, 2019 Lucas Richert, Erika Dyck 17 citations

This article places a spotlight on lysergic acid diethylamide (LSD) and American mental health in the 1970s, an era in which psychedelic science was far from settled and researchers continued to push the limits of regulation, resist change and attempt to revolutionise the mental health market-place. The following pages reveal some of the connections between mental health, LSD and the wider...

Acute Subjective and Behavioral Effects of Microdoses of Lysergic Acid Diethylamide in Healthy Human Volunteers

Biological Psychiatry June 3, 2019 Anya K. Bershad, Scott T. Schepers, Michael P. Bremmer et al. 176 citations

BackgroundNumerous anecdotal reports suggest that repeated use of very low doses of lysergic acid diethylamide (LSD), known as microdosing, improves mood and cognitive function. These effects are consistent both with the known actions of LSD on serotonin receptors and with limited evidence that higher doses of LSD (100-200 μg) positively bias emotion processing. Yet, the effects of such...

Cytochrome P450 enzymes contribute to the metabolism of LSD to nor-LSD and 2-oxo-3-hydroxy-LSD: Implications for clinical LSD use.

Biochemical Pharmacology June 1, 2019 Dino Luethi, Marius C. Hoener, Stephan Krähenbühl et al. 46 citations

In recent years, experimental research on lysergic acid diethylamide (LSD) in humans has gained new momentum. In humans, LSD is metabolized rapidly into several metabolites but knowledge of the involved metabolizing enzymes is limited. The aim of the current study was to identify the cytochrome P450 (CYP) isoforms involved in the metabolism of LSD to 6-norlysergic acid diethylamide (nor-LSD)...